Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Me too buddy, plenty to be excited about!
Merry Christmas HGEN Family, looking forward to 2022
Agreed Don, there is a lot to be looking at and excited about here.
Great Job, congrats and I hope this pays off!
Fantastic news today, it is validation of what we have been thinking all along. I cannot wait til the day we hear that Lenz is active in Hospital's where Healthcare & Patient's can make the decision to administer or not.
I just want to know that Patients and Healthcare Systems are able to provide access outside of a Clinical Trial/Compassionate Use setting. Hopefully Mayo and a few other Phase III Sites are taking advantage of Compassionate Use and providing to thier Patients now, but that process can be time consuming and convoluted when your working against the clock to properly administer, and it still has a level of Patients fears to overcome. It is frustrating wondering how many people may have needed Lenzilumab, but did not get it this far into the Pandemic.
Thanks Jay, that is very exciting if possible and regardless it's another great opportunity to bring awareness to Lenzilumab and Humanigen.
I liked Cameron's comments regarding Investigstors being suprised to say the least about the EUA not being initially approved.
Humanigen has been selected as a Quarterfinalists For the 2021 UCSF Healthcare Awards in the New Therapeutic Category. They are surrounded by some excellent companies.
Humanigen (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’
https://www.ucsfhealthhub.com/award-finalists/BoANOjwk
https://vimeo.com/613318856
Yes, I really enjoyed The Baird Presentation and am happy they made it available to shareholders. This was the response we needed after the past week. Frustrated that more people will have to wait, but still believe it is coming.
Nice work! Journey is going to take a little longer than expected, but I am still feeling we will arrive at our destination. I have also been confident for a very long time, so waiting is becoming my daily routine. Down big today on paper, but I really don't care.
Thanks Jay, I appreciate you sharing this today.
Might get bumpy for a bit, but we have a lot of positives to keep in sight.
MHRA
NIH ACTIV-5 Completion which was recently expanded based on Positive Interim Data, go figure.
CAR-T Trial with large players
GVHD Trial with Impact Group
CMML Trial
Mayo Clinic Support
This fight ain't over.
Let's rip this thing ! Nice adds
Take us to the moon, Nice work!
Those guys are definitely Not pumpers. They have been invested here for a long time, are very well informed and passionate about Lenzilumab's ability to prevent some of the worst Covid has to offer. I've been invested around the same as them before Phase III Trials started, and have seen Lenzilumab in Covid go from concept to where things are today. Over 600K Americans alone have died in the past year from Covid, and it's hard to standby and watch while people are still getting sick. Nothing wrong with being passionate about people having an opportunity to go home from the Hospital.
Keep up the fight Jay! We know what is sitting on a desk at FDA and the story needs to be told.
Several new tabs and videos were added to Humanigen website today.
https://www.cytokinestorm.humanigen.com/
You could add 100% success in Phase I Car-T , which I think will be viewed favorably if a buyout occurs, and we have yet to see which of the Big 3 Car-T Players join Phase II scheduled for later this year.
Great list. I'll give you two that come to mind for me
Pro: Thwaites paper on elevated GM-CSF
https://immunology.sciencemag.org/content/6/57/eabg9873
Con: 6 months to produce product
I think he is.
What is interesting to me is that Large Funds like Valiant Invested heavy & early here even with Nomis attached, and that speaks to the potential that they see with Lenzilumab to outweigh the risk/reward with Nomis attached.
It's a head scratcher for sure, and most of my conclusions aren't good. On one hand if they had nothing else then they might as well throw the kitchen sink at it with Toci, but on the other hand we have Lenz just sitting on an FDA Desk waiting for a stamp. This has been heartbreaking to since Oct of 2020 FDA & BARDA saw Lenz Phase III Interim Data showing success. I believe that if Lenz was Owned by Big Pharma it would have been rolled into action then or at least much faster then still sitting here in August 2021 waiting on patients to have a shot.
Just a thought but if we've used up all the Tocilizumab/Actemra supply then why are ICU'S still overflowing? Is it possible it works about as well as it's 4 failed trials proved?
Fingers crossed, that would be amazing if it were to happen. Probably to soon, but regardless of when it happens I am feeling confident that it is only a matter of time.
I am guessing as well here, but I assume they are fully enrolled since they had similar trail dates as the Lenz Arm. Lenz had an interim readout, and the trial was expanded following positive results with NIH and I'm not sure about ACTIV-5 A Risankizumab but think that trial not showing expanded is pretty telling.
A new ACTIV-5 C Trial was started this week with Danicopan.
https://clinicaltrials.gov/ct2/show/NCT04988035?term=ACTIV-5&draw=2&rank=1
ACTIV-5 A updated to Active - Not Recruiting.
This was the other NIH Selected Therapeutic of Risankizumab.
“The goal here is to identify as quickly as possible the experimental therapeutics that demonstrate the most clinical promise as COVID-19 treatments and move them into larger-scale testing,” said NIAID Director Anthony S. Fauci, M.D. “This study design is both an efficient way of finding those promising treatments and eliminating those that are not.”
The trial will test risankizumab, a monoclonal antibody developed by Boehringer Ingelheim (Ridgefield, Connecticut) and AbbVie (North Chicago, Illinois), in conjunction with the antiviral drug remdesivir, compared to a placebo plus remdesivir. The ACTIV-5/BET trial will also test the investigational monoclonal antibody lenzilumab, developed by Humanigen (Burlingame, California), with remdesivir, compared to placebo and remdesivir. Remdesivir has demonstrated clinical benefit for patients with severe COVID-19 requiring supplemental oxygen and is considered standard of care for hospitalized COVID-19 patients.
That is very sad news, I hope things improve quickly.
Yes, right now it's not approved yet so they cannot recommend until it's approved. It's an acknowledgement and once approved they will update. I view this as an important statement.
I took Pfizer and only side effects I had were about 48 hours after second dose I had chills and just felt rough overall, I went home and slept it off and have been fine since. It's definitely a personal choice and I have zero opinion on those that do vs those that don't. My main reason was that I work in public and interact with a lot of people daily, and also wanted to be able to do international travel without restrictions.
Welcome to the board and thanks for sharing your thoughts on their PR, very interesting to read and think about. Good Luck !
Yes, it is much more than a Covid stock. Covid Success just opens the doors much faster and gives revenue to Innovation and Trials in areas not possible without interference from Big Pharma Brass. That is something to be very excited about for sure.
Well said, obviously the Company succeeding is enough to get them to try and bash it. It's not working for me, and I doubt anyone here is swayed by it either. It's the equivalent of gnats flying around, they are annoying and should be dealt with, but they don't do anything else.
I don't know the answer to this question, but you definitely provided a really well thought out explanation. If anything I definitely learned something today! Thanks for sharing this.
Yes, it goes to show that the #1 Rated Hospital System in the World had their hands on a critical key to solving this puzzle. I am very happy that we were connected to Mayo Clinic. Even during times of questioning progress I always had to remind myself that Mayo Clinic, NIH and other prestigious Hospitals were connected to Lenz, and Trials continued to progress for a reason.
Lenzilumab is variant agnostic and treats the bodies overactive immune response to the virus and not the virus which is why Lenz is so important while the Vaccine's get tuned for variants.
Yes, media can say that they didn't know about little $HGEN and Lenzilumab, but what absolutely none of them can say is that they didn't look into what Phase III Clinical Trials for Covid-19 Treatment during a Worldwide Pandemic and 24 Hour News Cycle was Mayo Clinic working on. We are in the best hands possible. Once again the National Media failed and I for one will not forget.